Canadian Investment Regulatory Organization Trading Halt - MDNA

Stockhouse Apr 26 08:07 ET

Medicenna Therapeutics Up 13% After Flagging Presentations

Medicenna Therapeutics (MDNA.TO) was up near 13% on Wednesday after saying it will be presenting two abstracts, including an oral podium presentation, at the Annual Meeting of the American Society of

MT NewswiresApr 24 10:47 ET

Medicenna Announces Oral Presentation of MDNA11 Data From the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting

Oral presentation of MDNA11's Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity

GlobeNewswireApr 24 10:05 ET

Medicenna Therapeutics Presents Separate Updated Results and Preclinical Data; Shares Lost Near 12% Today

Medicenna Therapeutics (MDNA.TO), a clinical-stage immunotherapy company focused on the development of Superkines that saw its shares drop near 12% today, after trade Tuesday said it presented updated

MT NewswiresApr 9 16:44 ET

Medicenna Brief: Comes After Its Shares Lost Near 12% Today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And Masked Bi-Functional Anti-PD1-IL2 Superkine

04:32 PM EDT, 04/09/2024 (MT Newswires) -- Medicenna Brief: Comes After Its Shares Lost Near 12% today; Earlier Today Said Presented Updated Preclinical Data On MDNA113, A First-In-Class, Targeted And

MT NewswiresApr 9 16:32 ET

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity From Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

Medicenna Therapeutics presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions of the Phase 1/2 ABILITY-1 (A Beta-only IL-2 ImmunoTherapY) study evaluating MDNA11.

GlobeNewswireApr 9 16:30 ET